Table 5 Clinical data of included studies for the efficacy of SVR on the development of HCC in patients with CHC
Study | Nationality | Age | Duration of follow up | Study format | Genotype | NOS | Treatment | HCC/Total SVR | HCC/No SVR | Histology |
|---|---|---|---|---|---|---|---|---|---|---|
Nishiguchi S et al. (1995) [51] | Japan | Tx: 54.7, control: 57.3 (mean) | 2–7 years | RCT | 75.6% type 2 |  | IFN-α | 0/7 | 2/38 | HAI 11.7 in Tx, 11.8 in control (mean) |
Tanaka K et al. (1998) [52] | Japan | SVR: 47.7, no SVR: 51 (mean) | about 40Â months | P | unknown | 7 | lymphoblastoid IFN | 0/8 | 10/47 | LC |
Yoshida H et al. (1999) [30] | Japan | Tx: 49.5, control: 53.6 (mean) | median 4.3 years | R | 70.3% type 1 | 7 | IFN-α or IFN-β or combination | 10/789 | 79/1611 | F3,4: 33.1% in Tx, 33.8% in control |
Testino G et al. (2002) [16] | Italy | Tx: 55.3, control: 56.8 (mean) | mean 95.4 months | R | 55% type 1b, 45% type 2 | 8 | IFN-α | 3/11 | 12/40 | Child A LC |
Okanoue T et al. (2002) [53] | Japan | Tx: 50.4, control: 58.1 (mean) | Mean 5.6 years | R | unknown | 7 | IFN-α or lymphoblastoid | 4/426 | 110/994 | F3,4: 20.9% in SVR, 34.4% in control |
Coverdale SA et al. (2004) [36] | Australia | Tx: 37, control: 38 (median) | median 9 years | P | 39.6% type 1 | 7 | IFN-α | 1/50 | 25/334 | Scheuer fibrosis score 2 |
Shiratori Y et al. (2005) [38] | Japan | Tx: 57, control: 61 (median) | median 6.8 years | P | 71.9% type 1b | 8 | IFN-α or lymphoblastoid | 11/64 | 73/207 | unknown |
Yu ML et al. (2006) [39] | Taiwan | Tx: 46.9, control: 43.6 (mean) | mean 5.18–5.15 years | R | 46.2% type 1 | 8 | IFN-α with or without RBV | 12/715 | 39/342 | LC 15.6% in Tx, 12.1% in control |
Pradat P et al. (2007) [54] | Europe | 45–47 (mean) | 5–7 years | P | 49.2% type 1 | 6 | IFN/PegIFN with or without RBV | 0/91 | 17/266 | unknown |
Braks RE et al. (2007) [55] | France | 54.1 (mean) | mean 7.7 years | R | 61.1% type 1 | 8 | IFN-α with or without RBV, or PegIFN with RBV | 1/37 | 24/76 | Child A LC |
Bruno S et al. (2007) [56] | Italy | 54.7 (mean) | Mean 96.1 months | R | 71.8% type 1 | 8 | IFN-α | 7/124 | 122/759 | Child A LC |
Hasegawa E et al. (2007) [57] | Japan | 56 (median) | median 4.6 years | R | 65% 2a | 7 | IFN-α,β/lymphoblastoid with or without RBV | 3/48 | 16/57 | LC |
Veldt BJ et al. (2007) [58] | Europe and Canada | 48 (median) | median 2.1 years | R | 59% type 1 | 8 | IFN/PegIFN with or without RBV | 3/142 | 32/337 | Ishak 4–6 |
Floreani A et al. (2008) [59] | Italy | 44.5–55.7 (mean) | mean 23.4–25.2 months | R | 41.3% type 1 | 7 | PegIFN with RBV | 0/40 | 5/38 | unknown |
Sinn DH et al. (2008) [40] | Korea | 48.4–58.2 (mean) | median 55.2 months | R | 48.6% type 2 | 7 | IFN/PegIFN with or without RBV | 4/296 | 10/194 | F3,4: 49% in Tx, F4: 33% in control |
Kurokawa M et al. (2009) [60] | Japan | 55.8 (mean) | median 36.5 months | R | 72.9% type 1 | 7 | IFN-α with RBV | 4/139 | 21/264 | F3,4: 31.3% |
Asahina Y et al. (2010) [61] | Japan | 55.4 (mean) | mean 7.5 years | R | 69.6% type 1b | 8 | IFN-α,β with or without RBV, or PegIFN with RBV | 22/686 | 149/1356 | F3,4: 25.2% |
Kawamura Y et al. (2010) [62] | Japan | 50 (median) | median 6.7 years | R | unknown | 8 | IFN-α,β with or without RBV | 12/1081 | 61/977 | F1,2: 93.1% |
Cardoso AC et al. (2010) [63] | France | 55 (mean) | median 3.5Â years | R | 60% type 1 | 7 | IFN/PegIFN with or without RBV | 6/103 | 40/204 | F3,4: 100% |
Morgan TR et al. (2010) [64] | US | 48.6–49.6 (mean) | median 79–96 months | P | 87.2% type 1 | 8 | PegIFN with or without RBV | 2/140 | 33/386 | F3,4: 100% |
Di Martino V et al. (2011) [41] | France | unknown | median 59Â months | R | 57.9% type 1 | 7 | IFN with or without RBV, or PegIFN with RBV | 1/59 | 8/125 | 55.5%Â F2 or greater |
Velosa J et al. (2011) [65] | Portugal | 51.7 (mean) | mean 6.4Â years | R | 61% type 1 | 7 | IFN/PegIFN with or without RBV | 1/39 | 20/91 | compensated LC |
Iacobellis A et al. (2011) [66] | Italy | 59–62 (mean) | mean 51 months | P | 57.3% type 1 | 7 | PegIFN with RBV | 5/24 | 11/51 | decompensated LC |
Hung CH et al. (2011) [67] | Taiwan | 53 (median) | median 4.3Â years | R | 49% type 1 | 7 | IFN/PegIFN with or without RBV | 33/1027 | 54/443 | unknown |
Takahashi H et al. (2011) [68] | Japan | 55.4 (mean) | Mean 52 months | R | 74.9% type 1b | 7 | IFN-α,β/PegIFN with RBV | 1/89 | 12/114 | F3,4: 23.2% |
Backus LI et al. (2011) [69] | US | 51–53 (mean) | median 3.8 years | R | 72.1% type 1 | 6 | PegIFN with RBV | 223/7434 | 283/1440 | 13% LC |
Tateyama M et al. (2011) [42] | Japan | 57 (median) | mean 8.2Â years | R | 72.1% type 1b | 8 | IFN/PegIFN with or without RBV | 3/139 | 44/234 | F3,4: 34.1% |
Osaki Y et al. (2012) [70] | Japan | 59 (median) | median 4.1Â years | R | 59.9% type 1 | 7 | IFN/PegIFN with RBV | 1/185 | 22/197 | unknown |
van der Meer AJ et al. (2012) [71] | Europe and Canada | 48 (mean) | median 8.4 years | R | 68% type 1 | 8 | IFN/PegIFN with or without RBV | 7/125 | 76/405 | Ishak 4–6 |
Maruoka D et al. (2012) [43] | Japan | 50.4–54 (mean) | mean 9.9 years | R | 73.6% type 1 | 8 | IFN-α/IFN-β with or without RBV | 5/221 | 80/356 | F3,4: 24.3% in Tx, F4: 43.1% in control |
Cozen ML et al. (2013) [44] | US | 50.98 (mean) | mean 10 years | R | 68.7% type 1 | 8 | IFN-α with or without RBV | 2/69 | 9/90 | F3,4: 19% (30.2% in Tx, 10.1% in control) |
Alfaleh FZ et al. (2013) [72] | Saudi Arabia, Egypt | 48 (mean) | mean 63.8Â months | P | 30.6% type 4 | 8 | PegIFN with or without RBV | 0/62 | 4/95 | F3,4: 24.6% (27.1% in SVR, 31.1% in no SVR) |
Aleman S et al. (2013) [45] | Sweden | 51 (mean) | mean 5.3Â years | R | 50% type 1 | 8 | PegIFN with RBV | 6/110 | 26/193 | LC |
Di Marco V et al. (2016) [73] | Italy | 58 (mean) | median 7.6Â years | P | 83.4% type 1 | 8 | PegIFN with RBV | 7/108 | 92/336 | compensated LC |
Ikezaki H et al. (2016) [74] | Japan | 60–64 (median) | median 2.8 years | R | 52.7% in type 1 | 7 | IFN- β with RBV | 2/68 | 7/44 | F3,4: 30.9% in SVR, 72.7% in no SVR |